Yield10 Bioscience Inc Stock Price, News & Analysis

Yield10 Bioscience, an agricultural bioscience company, announced that its President and CEO, Dr. Oliver Peoples, will speak at the upcoming Maxim Group Global AgTech Conference on October 14, 2021. Dr. Peoples will participate in the "Innovative Food Technologies" panel from 10:30 am to 11:50 am ET. The virtual event features multiple panels and a keynote by Ambassador Kip E. Tom, CEO of Tom Farms. Interested attendees can register via M-Vest. Yield10 focuses on developing superior Camelina varieties for various agricultural applications.

Yield10 Bioscience announces that President and CEO Oliver Peoples, Ph.D. will present at the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13-15, 2021. The presentation will be available from 7:00 am ET on September 13, with an option for registered investors to engage in one-on-one meetings with management. Yield10 focuses on enhancing agricultural productivity through traits discovered via its 'Trait Factory' platform, specifically targeting improved Camelina varieties for various markets.

Yield10 Bioscience (NASDAQ:YTEN) reported its financial results for Q2 2021, highlighting key advancements in their Camelina platform. The company ended the quarter with $20.6 million in cash, down from $22.7 million. Yield10 faced an operational loss of $3.1 million, compared to $2.1 million in Q2 2020. R&D expenses rose to $1.7 million, while administrative costs increased to $1.6 million, partly due to higher stock-based compensation. The company is focused on scaling up Camelina for food and fuel applications and developing new oil content traits.

Yield10 Bioscience, Inc. (Nasdaq:YTEN) announced it will report its second quarter 2021 financial results on August 11, 2021.

The management will host a conference call at 4:30 p.m. ET to discuss financial results and corporate updates. A replay will be available shortly after the call and accessible until August 25, 2021.

Yield10 focuses on agricultural bioscience, particularly improving Camelina varieties for seed products, aiming to develop superior feedstock oils and PHA bioplastics.

Yield10 Bioscience (Nasdaq: YTEN) has successfully completed the planting of its 2021 Field Test and Seed Scale Up program at various sites across the U.S., Canada, and Argentina. This comprehensive program evaluates elite Camelina varieties and aims to assess seed yield and oil content traits. The company is also scaling up three Camelina varieties for larger plantings in 2022, including a CRISPR-edited trait that could enhance oil content by 4%. Harvest data is expected in Q3 2021, with insights to guide future developments.

Yield10 Bioscience, Inc. (Nasdaq:YTEN) announces two key appointments: Dr. Tichafa Munyikwa as Director of Regulatory Affairs and Dr. Nicholas Renegar as Director of Business Analytics and Operations. Dr. Munyikwa brings 25 years of experience in agriculture and has previously held regulatory roles at major firms. Dr. Renegar, recently earning a Ph.D. from MIT, is expected to enhance Yield10's supply chain analytics. Both appointments aim to strengthen Yield10's efforts in scaling seed production and commercialization of performance traits in Camelina.

Yield10 Bioscience, an agricultural bioscience company, announced that its Chief Science Officer, Dr. Kristi Snell, will present at the 2021 SEED conference on June 16. Her presentation will focus on advancements in plant-based PHB production using Camelina seeds. The research demonstrated that engineered Camelina lines can produce up to 6% PHA of mature seed weight. Dr. Snell emphasized that these findings could link large-scale agricultural production of biodegradable plastics to the global plastics market. Yield10 aims to scale PHA production to meet growing demand in environmentally friendly consumer products.

Yield10 Bioscience, a leader in agricultural bioscience, announced its CEO, Oliver Peoples, will present at the LD Micro Virtual Invitational XI on June 9, 2021, at 3:30 PM ET. The conference runs from June 8-10, 2021, and will focus on the company's innovative seed products and genetic trait discoveries aimed at enhancing agricultural yield. Yield10 aims to commercialize superior varieties of Camelina for oils and bioplastics while targeting major crop companies for licensing. Investors can register for the webcast and schedule meetings with the management team for further insights.

Yield10 Bioscience, Inc. (Nasdaq:YTEN) reported its first-quarter 2021 results, highlighting a cash position of $22.7 million, an increase from $9.7 million at year-end 2020. The company raised $12.7 million through a public offering and generated $3.9 million from warrant exercises. Notably, it reported a net loss of $2.6 million, or $0.60 per share, down from a $3.6 million loss in Q1 2020. Key initiatives include scaling up seed production for new Camelina varieties and advancing omega-3 oil technology for aquaculture, with regulatory compliance progressing. A conference call is scheduled for today at 4:30 p.m. (ET).